The biotech investing world will be glued to their computers Wednesday afternoon. About 5,000 datasets will be released simultaneously at 5 p.m. EDT, ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting.
The abstract drop, as it's known, has implications for companies large and small. Here's what analysts are watching.
Immunotherapies will continue to be the hot topic at this year's ASCO meeting, held May 29 to June 2 in Chicago. These medicines harness the immune system to fight cancer.
Since last year's ASCO, two new immunotherapies have been approved, Merck's Keytruda and Bristol-Myers Squibb's Opdivo. Analysts are expecting new data both on those medicines and others in the pipeline, specifically from Roche, AstraZeneca and Pfizer.